Melatonin is also a big immune system booster.

[GreenMachineX]

Taking melatonin for sleep is different then taking it for health benefits. Even though sleep definitely is good for health.

Yeah, but any more then that gives me side effects.

 

[Fernando Almaguer]

Taking melatonin for sleep is different then taking it for health benefits. Even though sleep definitely is good for health.

Doesn't it make you sleepy Vince?

 

[Vince]

Doesn't it make you sleepy Vince?

That was my fear if I took 100 milligrams of melatonin daily, would it make me fall asleep. It hasn't just done the opposite. A couple friends of mine try taking a 100 mg but it may their heart beat too fast so they drop down to 60 mg daily.

 

[GreenMachineX]

That was my fear if I took 100 milligrams of melatonin daily, would it make me fall asleep. It hasn't just done the opposite. A couple friends of mine try taking a 100 mg but it may their heart beat too fast so they drop down to 60 mg daily.

That happens to me with over 10mg.

 

[Vince]

That happens to me with over 10mg.

Are you on a calcium channel blocker?

 

[Vince]

Are you on a calcium channel blocker?

Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study

The results obtained in the present study show that the chronic evening ingestion of melatonin in hypertensive patients well controlled by nifedipine GITS induces a blood pressure increase and a heart rate acceleration. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014953/ Conclusions We...

www.excelmale.com

 

[GreenMachineX]

Are you on a calcium channel blocker?

No, that's interesting though.

 

[tareload]

Physiology of the Pineal Gland and Melatonin - Endotext - NCBI Bookshelf

The time of melatonin administration is critical, especially in chronic treatments, and the melatonin profile shows large interindividual variation; however, the profile of an individual is highly reproducible from day to day. Also, absorption, metabolism and excretion of melatonin vary between individuals and should be considered to get the desired clinical efficacy of the therapy. Ideally, although not feasible in a daily clinical practice, DLMO should be determined for each individual, and used as a timing reference for the prescription of melatonin. Alternatively, the time each individual goes to sleep could determine the time of administration of melatonin; it is advisable to take oral melatonin around 45 minutes to 1 hour before the usual bedtime (time to reach maximal plasma concentrations following oral immediate-release formulations). Moreover, the duration of the pharmacological profile should last until the usual wake time of the patient; thus, the type of pharmaceutical formulation (slow or fast release) is also an important consideration. Route of administration, as well as age, liver function and potential drug interactions (since melatonin is metabolized in the liver), may influence plasma melatonin levels and should be taken into account (95). Sensitivities and pharmacokinetics of melatonin vary between individuals, and a lower dose of 0.3-0.5 mg might be more effective than higher doses in many subjects.


There is no general consensus regarding dosage. A wide range of dose formulations are available, and the usage varies depending on the clinical application. Low doses 0.1 to 0.3 mg/d that produce physiological melatonin concentrations can be used for central clock synchronization; doses ranging from 0.6 to 5 mg/d for sleep disorders, or doses as high as 300 mg/d for neurodegenerative disorders (amyotrophic lateral sclerosis) (96,97). In most clinical trials or studies using melatonin, it is well accepted that in general melatonin lacks toxic adverse events, and it is a safe drug at most of the usual tested doses from 0.5 to 5 mg/d (98). Whether dosage should be changed in chronic melatonin treatment according to the annual season requires further investigation; further studies are needed on the undesirable consequences of melatonin suppression in the long term.

 

[Vince]

Physiology of the Pineal Gland and Melatonin - Endotext - NCBI Bookshelf

The time of melatonin administration is critical, especially in chronic treatments, and the melatonin profile shows large interindividual variation; however, the profile of an individual is highly reproducible from day to day. Also, absorption, metabolism and excretion of melatonin vary between individuals and should be considered to get the desired clinical efficacy of the therapy. Ideally, although not feasible in a daily clinical practice, DLMO should be determined for each individual, and used as a timing reference for the prescription of melatonin. Alternatively, the time each individual goes to sleep could determine the time of administration of melatonin; it is advisable to take oral melatonin around 45 minutes to 1 hour before the usual bedtime (time to reach maximal plasma concentrations following oral immediate-release formulations). Moreover, the duration of the pharmacological profile should last until the usual wake time of the patient; thus, the type of pharmaceutical formulation (slow or fast release) is also an important consideration. Route of administration, as well as age, liver function and potential drug interactions (since melatonin is metabolized in the liver), may influence plasma melatonin levels and should be taken into account (95). Sensitivities and pharmacokinetics of melatonin vary between individuals, and a lower dose of 0.3-0.5 mg might be more effective than higher doses in many subjects.


There is no general consensus regarding dosage. A wide range of dose formulations are available, and the usage varies depending on the clinical application. Low doses 0.1 to 0.3 mg/d that produce physiological melatonin concentrations can be used for central clock synchronization; doses ranging from 0.6 to 5 mg/d for sleep disorders, or doses as high as 300 mg/d for neurodegenerative disorders (amyotrophic lateral sclerosis) (96,97). In most clinical trials or studies using melatonin, it is well accepted that in general melatonin lacks toxic adverse events, and it is a safe drug at most of the usual tested doses from 0.5 to 5 mg/d (98). Whether dosage should be changed in chronic melatonin treatment according to the annual season requires further investigation; further studies are needed on the undesirable consequences of melatonin suppression in the long term.

View attachment 20612

Yep, I agree. It depends on why your supplementing with melatonin for sleep or for health reasons. Completely different circumstances.